Dilated cardiomyopathy is a medical condition in which the heart's muscle tissue becomes stretched, weakened, or has some other structural defect. Dilated cardiomyopathy most commonly occurs in people with a history of heart disease and may also be hereditary. There is currently no known cause for Dilated Cardiomyopathy, but there are several possible genetic or environmental factors that may increase the chance of developing Dilated Cardiomyopathy or even heart disease. A few of the possible risk factors include:
Dilated cardiomyopathy can produce symptoms such as pain or discomfort in the chest, usually near the center of the chest, dizziness, and irregular heartbeat, nausea, vomiting, and swelling in the abdomen. Abnormal heart rhythms may also be present, particularly faster heartbeats or shallow, irregular rhythms. When Dilated Cardiomyopathy occurs, there are three types of treatments. These include surgery, medications, and lifestyle changes.
Owing the increase in congestive heart failure cases in the world is the main factor that is driving the growth of the global dilated cardiomyopathy market. For instance, according to the European Society of Cardiology, around 26 million people in the world are suffering from heart failure. Moreover, continuous research and development in the field of medical studies to launch accurate drugs to treat the condition are also enhancing the growth of the global dilated cardiomyopathy market.
Surgery for Dilated Cardiomyopathy involves the surgical removal of affected tissue, such as a lung or a section of the heart. Medications and lifestyle changes, however, are most often used to treat Dilated Cardiomyopathy. Oftentimes, patients are given a shock collar to help lower their heart rate, as well as fluid medication, and often a course of anti-arrhythmia medicine, such as Atripla. Some patients with Dilated Cardiomyopathy do not respond to medication or physical therapy and are placed on a waiting list for surgery. Waiting for the symptoms of Dilated Cardiomyopathy to subside before seeking treatment can result in a significant loss of quality of life. However, the unavailability of accurate drugs for treating this condition is the main restraining factor that is hindering the growth of the global dilated cardiomyopathy market.
Owing to the increase of cardiovascular issues in the region, North America is witnessing high demand in the global dilated cardiomyopathy market. For instance, according to the Centers for Disease Control and Prevention, around 6.2 million adults in the United States region suffer from heart failure. Moreover, continues developments in the healthcare sector in the region are also boosting the market growth. Owing to such factors there have been significant developments in the global dilated cardiomyopathy market. For instance, in August 2019, MyoKardia, Inc., introduced the 2nd Annual Myoseeds Research Grant Program, for promoting independent research in biology.